chlorido(5,7-dichloro-8-quinolinolato-κN1,κO8)(η6-p-cymene)ruthenium(II) | 1202404-37-2

• 英文名称: chlorido(5,7-dichloro-8-quinolinolato-κN1,κO8)(η6-p-cymene)ruthenium(II)
• 英文别名: chlorido(5,7-dichloro-8-quinolinolato-κN¹,κO⁸)(η⁶-p-cymene)ruthenium(II)；chlorido(5,7-dichloro-8-quinolinolato-κ²N,O)(η⁶-p-cymene)ruthenium(II)；[(η6-p-cymene)Ru(η2-N,O-5,7-dichloro-8-hydroxyquinolate)Cl]；[η6-MeC6H4(i-Pr))Ru(η2-NC9H4Cl2O)Cl]
• CAS: 1202404-37-2
• 化学式: C₁₉H₁₈Cl₃NORu
• 分子量: 483.787
• InChiKey: DWZATKGBWABYLY-UHFFFAOYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  None
• 重原子数：
  None
• 可旋转键数：
  None
• 环数：
  None
• sp3杂化的碳原子比例：
  None
• 拓扑面积：
  None
• 氢给体数：
  None
• 氢受体数：
  None

反应信息

• 作为产物：
  描述：

  [ruthenium(II)(η⁶-1-methyl-4-isopropyl-benzene)(chloride)(μ-chloride)]₂ 、 potassium 5,7-dichloro-8-hydroxyquinolate 以 四氢呋喃 为溶剂， 以72%的产率得到chlorido(5,7-dichloro-8-quinolinolato-κN1,κO8)(η6-p-cymene)ruthenium(II)
  参考文献：
  名称：

  芳烃钌肟酸酯络合物：水溶液中二氧化碳加氢的合成，分子结构和催化活性

  摘要：

  的芳烃钌oxinato类型的络合物两个家庭[（η 6 -arene）的Ru（η 2 - Ñ，ö -L）CL]和[（η 6 -arene）的Ru（η 2 - Ñ，ö -L）（ OH 2）] +已从双核的前体合成的[（η 6 -arene）的RuCl 2 ] 2（芳烃= 对位-cymeme或六甲基苯）和相应的牛LH（LH = 8-羟基喹啉，5-氯-8-羟基喹啉，5,7-二氯-8-羟基喹啉，5-硝基-8-羟基喹啉，5,7-二甲基-8 -羟基喹啉，5,7-二氯-2-甲基-8-羟基喹啉）。中性氯络合物的分子结构[（η 6 -C 6我6）的Ru（η 2 - Ñ，ö -L）CL]（LH = 8-羟基喹啉，5,7-二氯-2-甲基-8-羟基喹啉）和[（η 6 -MeC 6 ħ 4镨我）的Ru（η 2 - ñ，ö-L）CL]（LH = 5,7-二氯-2-甲基-8-羟基喹啉）以及那些阳离子AQUA衍生物[（η 6

  DOI：

  10.1016/j.jorganchem.2009.09.008

文献信息

• Impact of the Halogen Substitution Pattern on the Biological Activity of Organoruthenium 8-Hydroxyquinoline Anticancer Agents
  作者：Mario Kubanik、Hannah Holtkamp、Tilo Söhnel、Stephen M. F. Jamieson、Christian G. Hartinger

  DOI：10.1021/acs.organomet.5b00868

  日期：2015.12.14

  8-Hydroxyquinoline and its derivatives have a broad variety of pharmacological properties, which make them an ideal bioactive building block in the development of metal-based anticancer drugs. In this account we aimed to rationalize the antiproliferative efficacy of organoruthenium compounds featuring 8-hydroxyquinoline-derived ligands and to elucidate structural determinants by using biological assays and bioanalytical methods. By systematically varying the halide substitution pattern at the 5- and 7-positions of the 8-hydroxyquinoline ligand, as well as the halido leaving group, a series of 5,7-dihalido-8-hydroxyquinoline Ru-II(eta(6)-p-cymene) complexes were obtained. Studies on their cytotoxic activity revealed the minor impact of the substitution pattern (with the exception of complexes of 8-hydroxyquinoline) on their activity. Notably, the cellular accumulation showed no correlation with the cytotoxic activity, while the nature of the halido leaving group only had a significant influence in the case of the 8-hydroxyquinoline organoruthenium compounds. However, the compounds were shown to be very stable under a wide variety of pH conditions, making them possible candidates for further development as orally active anticancer agents.